Novartis AG ROE 2010-2022 | NVS

Current and historical return on equity (ROE) values for Novartis AG (NVS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Novartis AG ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $22.98B $63.01B 36.85%
2022-03-31 $24.18B $61.70B 40.21%
2021-12-31 $24.02B $67.82B 41.87%
2021-09-30 $9.81B $56.94B 17.97%
2021-06-30 $8.98B $54.13B 16.64%
2021-03-31 $7.96B $50.59B 14.75%
2020-12-31 $8.07B $56.67B 14.94%
2020-09-30 $7.10B $54.55B 13.22%
2020-06-30 $7.21B $53.89B 13.54%
2020-03-31 $12.14B $50.98B 23.06%
2019-12-31 $11.73B $55.55B 22.67%
2019-09-30 $11.80B $52.60B 20.52%
2019-06-30 $11.38B $51.50B 17.82%
2019-03-31 $12.35B $47.31B 17.59%
2018-12-31 $12.61B $78.69B 16.55%
2018-09-30 $13.39B $78.02B 17.83%
2018-06-30 $13.85B $76.90B 18.80%
2018-03-31 $8.06B $71.21B 11.21%
2017-12-31 $7.70B $74.23B 10.84%
2017-09-30 $6.68B $72.37B 9.38%
2017-06-30 $6.54B $69.98B 9.10%
2017-03-31 $6.37B $67.65B 8.78%
2016-12-31 $6.71B $74.89B 9.12%
2016-09-30 $6.81B $75.07B 9.18%
2016-06-30 $6.76B $72.53B 9.06%
2016-03-31 $6.79B $71.89B 8.91%
2015-12-31 $17.78B $77.12B 23.01%
2015-09-30 $18.22B $76.79B 24.06%
2015-06-30 $19.56B $78.83B 26.29%
2015-03-31 $20.27B $76.44B 28.04%
2014-12-31 $10.21B $70.84B 14.42%
2014-09-30 $10.75B $71.42B 14.99%
2014-06-30 $9.76B $70.52B 13.57%
2014-03-31 $9.72B $70.34B 13.56%
2013-12-31 $9.18B $74.47B 12.95%
2013-09-30 $9.13B $72.18B 13.13%
2013-06-30 $9.29B $69.63B 13.60%
2013-03-31 $9.42B $67.15B 14.07%
2012-12-31 $9.27B $69.26B 14.05%
2012-09-30 $8.29B $67.21B 12.72%
2012-06-30 $8.36B $64.24B 12.89%
2012-03-31 $8.42B $63.20B 12.83%
2011-12-31 $8.94B $65.94B 13.52%
2011-09-30 $10.11B $66.14B 15.07%
2011-06-30 $9.92B $67.09B 14.78%
2011-03-31 $9.63B $65.34B 14.98%
2010-12-31 $9.79B $69.77B 15.86%
2010-09-30 $9.93B $66.22B 16.92%
2010-06-30 $9.75B $55.82B 17.59%
2010-03-31 $9.37B $55.22B 17.32%
2009-12-31 $8.40B $57.46B 16.19%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84